Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (1-10 of 384) with videos related to

Pageof 39
Sort By:
Seminars in Thrombosis and Hemostasis|January 1, 1996
Current trends in antithrombotic drug and device developmentJ Fareed
Seminars in Thrombosis and Hemostasis|January 1, 1985
Heparin, its fractions, fragments and derivatives. Some newer perspectivesJ Fareed
Seminars in Thrombosis and Hemostasis|April 1, 1985
Development of heparin fractions: some overlooked considerationsJ Fareed
Seminars in Thrombosis and Hemostasis|October 1, 1991
Venous thromboprophylaxis in the 1990s: a perspectiveJ Fareed
Journal Des Maladies Vasculaires|January 1, 1987
[Low molecular weight heparin fractions. Comparative preclinical study of various parameters]J Fareed
Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1989
Recent development in antithrombotic therapyJ Fareed
Thrombosis Research|May 1, 1995
Determination of specific activity of recombinant hirudin using a thrombin titration methodL Iyer, J Fareed
Thrombosis Research|July 15, 1992
Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamineA Racanelli, J Fareed
Thrombosis Research|November 1, 1992
Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfateA Racanelli, J Fareed
Thrombosis and Haemostasis|October 1, 1996
Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosisB Kaiser, J Fareed
Pageof 39

Showing results (1-10 of 384) with videos related to

Sort By:
Pageof 39
Seminars in Thrombosis and Hemostasis|January 1, 1996
Current trends in antithrombotic drug and device developmentJ Fareed
Seminars in Thrombosis and Hemostasis|January 1, 1985
Heparin, its fractions, fragments and derivatives. Some newer perspectivesJ Fareed
Seminars in Thrombosis and Hemostasis|April 1, 1985
Development of heparin fractions: some overlooked considerationsJ Fareed
Seminars in Thrombosis and Hemostasis|October 1, 1991
Venous thromboprophylaxis in the 1990s: a perspectiveJ Fareed
Journal Des Maladies Vasculaires|January 1, 1987
[Low molecular weight heparin fractions. Comparative preclinical study of various parameters]J Fareed
Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1989
Recent development in antithrombotic therapyJ Fareed
Thrombosis Research|May 1, 1995
Determination of specific activity of recombinant hirudin using a thrombin titration methodL Iyer, J Fareed
Thrombosis Research|July 15, 1992
Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamineA Racanelli, J Fareed
Thrombosis Research|November 1, 1992
Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfateA Racanelli, J Fareed
Thrombosis and Haemostasis|October 1, 1996
Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosisB Kaiser, J Fareed
Pageof 39